Atlas Venture Life Science Advisors’s Generation Bio GBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-827,946
| Closed | -$4.7M | – | 8 |
|
|
2025
Q4 | $4.7M | Hold |
827,946
| – | – | 0.54% | 8 |
|
|
2025
Q3 | $5.07M | Sell |
827,946
-2
| -0% | -$10 | 0.67% | 7 |
|
|
2025
Q2 | $2.65M | Hold |
827,948
| – | – | 0.4% | 11 |
|
|
2025
Q1 | $3.35M | Hold |
827,948
| – | – | 0.64% | 12 |
|
|
2024
Q4 | $8.78M | Hold |
827,948
| – | – | 1.07% | 8 |
|
|
2024
Q3 | $20.5M | Hold |
827,948
| – | – | 1.9% | 8 |
|
|
2024
Q2 | $23.3M | Hold |
827,948
| – | – | 2.46% | 8 |
|
|
2024
Q1 | $33.7M | Hold |
827,948
| – | – | 3.11% | 9 |
|
|
2023
Q4 | $13.7M | Hold |
827,948
| – | – | 1.63% | 10 |
|
|
2023
Q3 | $31.4M | Hold |
827,948
| – | – | 4.86% | 8 |
|
|
2023
Q2 | $45.5M | Hold |
827,948
| – | – | 5.67% | 8 |
|
|
2023
Q1 | $35.6M | Buy |
827,948
+60
| +0% | +$2.9K | 4.82% | 9 |
|
|
2022
Q4 | $32.5M | Hold |
827,888
| – | – | 3.92% | 10 |
|
|
2022
Q3 | $44M | Hold |
827,888
| – | – | 4.85% | 7 |
|
|
2022
Q2 | $54.3M | Hold |
827,888
| – | – | 9.08% | 5 |
|
|
2022
Q1 | $60.8M | Hold |
827,888
| – | – | 7.68% | 4 |
|
|
2021
Q4 | $58.6M | Buy |
+827,888
| New | +$145M | 5.38% | 6 |
|
Other funds holding GBIO
Atlas Venture Life Science Advisors's GBIO Position: Q1 2026 in Review
Atlas Venture Life Science Advisors sold out of Generation Bio (GBIO) in Q1 2026, closing a stake of 827,946 shares — an estimated $4.7M sold.
Atlas Venture Life Science Advisors first reported a position in GBIO in Q4 2021 and held it in 17 quarters. The position peaked at $60.8M in Q1 2022. 2 funds tracked by Wall St. Rank hold GBIO as of Q1 2026.
- Atlas Venture Life Science Advisors reported no remaining Generation Bio position as of Q1 2026 after selling out during the quarter.
- Atlas Venture Life Science Advisors sold 827,946 Generation Bio shares in Q1 2026, an estimated $4.7M.
- Atlas Venture Life Science Advisors first reported a position in Generation Bio in Q4 2021 and held it in 17 quarters.
- Atlas Venture Life Science Advisors's Generation Bio position peaked at $60.8M in Q1 2022.
- 2 funds tracked by Wall St. Rank held Generation Bio as of Q1 2026.
Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2026, filed 14 May 2026.